A molecular glue that makes the cell’s own disposal machinery destroy cancer-driving proteins rather than merely blocking them — and the first of its class to reach patients.
In warm autoimmune hemolytic anemia the body destroys its own red cells and there was nothing approved to stop it. Imaavy blocks the recycling system that keeps the guilty antibodies alive.
K2 does not discover drugs. It licenses them, mostly from China, and its new CEO ran the company behind one of the first China-to-US commercial successes.
A foxglove extract used since the eighteenth century, at less than 10 cents a day, cut heart-failure hospitalisations by about a quarter in a modern randomised trial.
Three neurotransmitters at once, no stimulant. The first genuinely new mechanism in ADHD in years, and the first that adds serotonin.
For a disease with no alternative therapy, a delayed shipment is not an inconvenience. Enzyme levels fall between infusions by design.
42% of patients on the drug reached zero heavy-drinking days. In a condition where three medications exist and few people take them, that number matters.
Biohaven sold its most advanced drug months before the pivotal trial reads out. That timing is the story — a company with a shrinking runway does not get to wait for good news.
The tumour shortens one messenger RNA, which destroys the flag T cells look for. Forcing the RNA back to full length puts the flag back.
Let the mosquito deliver a live parasite, then stop it with a drug at the late liver stage. The immune system sees the whole organism; the patient never gets sick.
Prior authorization is the paperwork gate between a doctor’s decision and a patient’s treatment. R1 is buying an AI company that claims a 96% first-pass approval rate on getting through it.
Retrieval, not training. The distinction determines who owns what, and it is why this deal was possible when others have ended in court.